abc27

Vivex Biologics, Inc. Completes Subject Enrollment for its ASCEND Trial Evaluating VIA Disc NP™ for Symptomatic Disc Degeneration

MIAMI, July 29, 2025 (GLOBE NEWSWIRE) -- Vivex Biologics, Inc., a leader in developing and delivering innovative allografts, today announced that it has completed subject enrollment in its ASCEND ...
Business Insider

Vivex Biologics Treats First Patient in its Restore Trial Evaluating VIA Disc NP™ for Patients with Degenerative Disc Disease

MIAMI, Sept. 30, 2025 (GLOBE NEWSWIRE) -- Vivex Biologics, a leader in developing and delivering innovative allografts, today announced that it has treated the first patient in its Restore U.S.
New Atlas

Non-surgical treatment eases chronic back pain & restores function

A clinical trial on the VIA Disc NP treatment for discogenic back pain has shown impressive results, significantly reducing pain and improving back function. The non-surgical, minimally invasive ...
Business Insider

VIVEX Biologics Publishes Initial Clinical Results of VIA Disc in The International Journal of Spine Surgery

First-ever published 12-month results from Level 1 intradiscal study for treating patients with one or two level symptomatic degenerative disc disease Early evidence suggests greater than 70% ...
MarketWatch

Vivex Biologics Treats First Patient in its Restore Trial Evaluating VIA Disc NP(TM) for Patients with Degenerative Disc Disease

The MarketWatch News Department was not involved in the creation of this content. MIAMI, Sept. 30, 2025 (GLOBE NEWSWIRE) -- Vivex Biologics, a leader in developing and delivering innovative allografts ...